OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Statistics

Total Valuation

OncoSil Medical has a market cap or net worth of AUD 28.24 million. The enterprise value is 23.20 million.

Market Cap	28.24M
Enterprise Value	23.20M

Important Dates

The next estimated earnings date is Friday, November 28, 2025.

Earnings Date	Nov 28, 2025
Ex-Dividend Date	n/a

Share Statistics

OncoSil Medical has 18.82 million shares outstanding. The number of shares has increased by 97.77% in one year.

Current Share Class	18.82M
Shares Outstanding	18.82M
Shares Change (YoY)	+97.77%
Shares Change (QoQ)	+19.93%
Owned by Insiders (%)	7.38%
Owned by Institutions (%)	27.48%
Float	16.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.39
PB Ratio	9.10
P/TBV Ratio	9.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.54
EV / Sales	15.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.92

Financial Position

The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.02.

Current Ratio	1.67
Quick Ratio	1.57
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-17,204.83

Financial Efficiency

Return on equity (ROE) is -385.20% and return on invested capital (ROIC) is -236.34%.

Return on Equity (ROE)	-385.20%
Return on Assets (ROA)	-136.02%
Return on Invested Capital (ROIC)	-236.34%
Return on Capital Employed (ROCE)	-483.65%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.22
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -71.15% in the last 52 weeks. The beta is 1.18, so OncoSil Medical's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	-71.15%
50-Day Moving Average	1.55
200-Day Moving Average	1.57
Relative Strength Index (RSI)	41.22
Average Volume (20 Days)	11,592

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OncoSil Medical had revenue of AUD 1.54 million and -15.10 million in losses. Loss per share was -1.38.

Revenue	1.54M
Gross Profit	-718,376
Operating Income	-15.09M
Pretax Income	-15.10M
Net Income	-15.10M
EBITDA	-15.08M
EBIT	-15.09M
Loss Per Share	-1.38

Balance Sheet

The company has 5.11 million in cash and 69,915 in debt, giving a net cash position of 5.04 million or 0.27 per share.

Cash & Cash Equivalents	5.11M
Total Debt	69,915
Net Cash	5.04M
Net Cash Per Share	0.27
Equity (Book Value)	3.10M
Book Value Per Share	0.22
Working Capital	2.70M

Cash Flow

In the last 12 months, operating cash flow was -12.06 million and capital expenditures -14,964, giving a free cash flow of -12.08 million.

Operating Cash Flow	-12.06M
Capital Expenditures	-14,964
Free Cash Flow	-12.08M
FCF Per Share	-0.64

Margins

Gross Margin	-46.79%
Operating Margin	-982.80%
Pretax Margin	-983.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoSil Medical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-97.77%
Shareholder Yield	-97.77%
Earnings Yield	-53.47%
FCF Yield	-42.77%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 3, 2025. It was a reverse split with a ratio of 0.0025.

Last Split Date	Jun 3, 2025
Split Type	Reverse
Split Ratio	0.0025

Scores

OncoSil Medical has an Altman Z-Score of -22.86 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-22.86
Piotroski F-Score	2